We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Acute Heart Failure Drug Trials Should Include Co-Primary Endpoints, EMA Says
Acute Heart Failure Drug Trials Should Include Co-Primary Endpoints, EMA Says
November 9, 2012
Developers of acute heart failure drugs should conduct double-blind, randomized Phase III trials with co-primary endpoints, rather than composite endpoints, according to a European Medicines Agency (EMA) draft guideline.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor